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Background
Complex genetic diseases are deﬁ ned as those inﬂ uenced 
by multiple genes and by environmental eﬀ ects. In the 
past, individual genetic variants contributing to the risk 
of disease were usually not known, so the contribution of 
genes to disease was recognised through increased risk of 
disease in relatives of aﬀ ected probands. Modeling 
allowed the genetic component of disease to be expressed 
as variance components and heritabilities. However, with 
the advent of genome-wide association studies (GWAS), 
individual genetic risk factors, or at least markers linked 
to them, are identiﬁ able. Th is provides a description of 
the genetics in quite diﬀ erent terms to the traditional use 
of variance components. Th e new description is based on 
the frequency of individual risk alleles and their eﬀ ect 
sizes expressed either as the relative risk or the odds 
ratio.
A clear picture is emerging as more and more results 
from GWAS are published about the eﬀ ect sizes of 
individual loci that contribute to disease. For instance, 
allelic odds ratios at markers are typically estimated to be 
<1.5 and risk alleles can be the minor or major frequency 
allele. At present, there is little evidence of departure 
from a multiplicative model (on the observed disease risk 
scale) of disease [1], within and across loci, but this is 
based on combining only a limited number of markers 
and explaining only a small proportion of the genetic 
variance.
To reconcile the traditional description in terms of risk 
to relatives with the description based on individual risk 
loci, we need a model of how the risk loci combine to 
determine the total genetic risk for an individual person. 
Simple models are unlikely to be a true representation of 
complex diseases, but they allow us to explore the 
boundaries of possible genetic architectures that remain 
consistent with observed data. Several models are com-
monly used. Unfortunately the terms used to describe 
these models are confusing. For example, the terms 
‘additive’ and ‘multiplicative’ can both be used to describe 
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the same fundamental model because a multiplicative 
model on the observed disease risk scale (the ‘risk scale’) 
is equivalent to an additive model on the logarithm of the 
risk scale. Moreover, the multiplicative model can imply 
multiplicativity of allelic relative risks [2,3], or of odds 
ratios [4], or that risk alleles are needed at all loci in order 
to develop disease [5].
In this paper we show how the parameters for the 
individual risk loci (eﬀ ect, allele frequency and number 
of loci) plus a model for combining the eﬀ ects of 
individual loci determine the traditional parameters such 
as risk to relatives. Th e purpose of the paper is to 
compare the predictions made by diﬀ erent models and to 
determine which model(s) best ﬁ t the observed data. 
Before explaining the diﬀ erent models of genetic risk we 
ﬁ rst describe the genetic population parameters of 
recurrence risk to relatives.
Recurrence risk to relatives
Th e genetic epidemiology of complex genetic diseases can 
be described in terms of the observable parameters of 
disease prevalence and relative risk to relatives of diseased 
probands (Table 1). Risks of disease in relatives provide an 
upper limit to the genetic component because common 
environmental factors may also increase risk to relatives. 
However, for the purposes of this paper we will assume 
risk to relatives is due to their genetic similarity. Th e 
recurrence risk for relatives of type R (λR) is calculated as 
the ratio of the prevalence in the population of relatives of 
type R (KR) to the overall population prevalence (K), λR = 
KR/K. As the maximum value for KR is 1 and the prevalence 
in monozygotic (MZ) twins of probands, KMZ, will be the 
highest of all relative types, there is a constraint that λMZ 
≤  1/K, so that higher values of λMZ (and all λR) are often 
observed for diseases of lower prevalence (Table 1). 
Despite being observable, the parameters K and λR are 
subject to considerable sampling variance. For Table 1, we 
have tried, where possible, to take estimates from reviews 
or large studies, but large study samples simply do not 
exist for low prevalence disorders - for example, the λMZ for 
ankylosis spondylitis [6] is based on only 27 MZ twin 
probands. Nonetheless, we can use these examples as a 
guide to assessing realistic scenarios for disease.
Th e risk to diﬀ erent classes of relatives (that is, λR) 
depends on the magnitude of genetic variance compo-
nents. Th e total genetic variance is traditionally decom-
posed into additive variance, dominance variance and 
various types of epistatic variance. Th e relationship 
between relative risks and variance components on risk 
scale was derived by James [7], who showed that the 
probability of disease in relatives of type R can be 
expressed as:
KR = K + cov(X,R)/K
with cov(X,R) the genetic covariance between the 
proband, X , and a relative, R. For individuals X and R we 
Table 1. Recurrence risk (λR ) to relatives (of type R) for several common complex genetic diseases ordered by prevalence (K)
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Major depression (population 
cohort)
[27] 0.24 2 1.3 0.32 3.3 1.2 0.34
Age related macular 
degeneration 
[28,29] 0.12 4.7 2.1 0.50 3.4 1.1 0.64
Myocardial infarction [30] 0.056 4.6 3.2 0.21 1.6 0.4 0.72
Breast cancer [31] 0.036 4.1 2.2 1.9 0.12 1.3 2.6 0.8 0.37
Type II diabetes [32] 0.028 10.4 3.5 0.27 3.8 0.8 0.58
Asthma [33] 0.019 6.6 3.4 0.11 2.3 0.6 0.49
Rheumatoid arthritis [34] 0.01 12.2 3.6 0.11 4.3 0.9 0.42
Bipolar disorder [5] 0.01 60 7 7 0.60 1.0 10 1.2 0.70
Schizophrenia [3] 0.0085 52.1 8.6 10 0.44 0.8 6.7 0.7 0.76
Type I diabetes [35] 0.005 79 14 0.39 6.0 0.4 0.85
Multiple sclerosis [36] 0.001 190 20 0.19 ~1 9.9 0.5 0.68
Crohn’s disease [37] 0.001 600 64 0.60 10 0.1 1.00
Ankylosis spondylitis [6] 0.001 630 82 79 0.63 1.0 7.8 0.1 1.00
Systemic lupus erythematosus [38] 0.001 29 27 1.1 0.80
[39,40] 0.0003 774 65 0.24 12 0.2 0.84
aThe maximum prevalence for KMZ is 1, so λMZ = KMZ/K is constrained to be ≤1/K. λMZ was calculated from probandwise concordance rates KMZ and prevalence rates if λMZ 
was not directly reported. bEstimated from either sibling, dizygotic twin or fi rst degree relative risks. cBroad sense heritability on the risk scale (Equation 1). dThis ratio is 
expected to be 1 in the absence of dominance eff ects on the risk scale. eThis ratio is expected to be 2 under an additive model on the risk scale. fThis ratio is expected 
to be 1 under the unconstrained Risch model. gCalculated from the estimates of K and λSib [41,42], constrained to a maximum of 1.
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deﬁ ne r to be the relationship between them, r = 2 × 
Probability of identity by descent (IBD) of random alleles 
(that is, twice the ancestry or kinship coeﬃ  cient) and u is 
the probability of both alleles being IBD at a locus, so that







where VA(k)D(l) denotes the genetic variance component 
with k A and l D terms [3,5,8,9]. So for R = MZ twin, r = 
1, u =1, then:
Cov(X, MZ) = 
VA01+VD01+VAA01+VAD01+VDD01+VAAD01+VAAA01+…=VG01
We use the ‘01’ subscript to emphasize the observed zero-
one (not diseased-diseased) risk scale of measurement. 
Th erefore, an estimate of the broad sense heritability on 
the risk scale (H 201) is:
              VG01      (λMZ – 1)K
2       (λMZ – 1)KH 201 = _______ = ____________________ = ____________________       (Equation 1)              VP01         K(1 – K)            (1 – K)
since the phenotypic variance on the risk scale is VP01 = 
K(1 – K). For the diseases listed in Table 1, H 201 ranges 
from 0.11 to 0.63, but the heritability on this scale is not a 
normally reported statistic because of its dependence on 
disease prevalence. When the relatives are sibs, R = Sib, 
r = ½, u = ¼, then:
                        VA01    VD01   VAA01    VAD01   VDD01  VAAA01  VAAD01Cov(X, Sib) = _____ + _____ + ______ + ______ + ______ + ______ + ______ + …                          2        4        4         8       16        8       16
When the relatives are parents or oﬀ spring, R = OP, r 
=1/2, u = 0, then:
                                            VA01    VAA01   VAAA01Cov(X, OP) = _____ + ______ + ________ + …                                              2         4         8 
Th erefore, λSib ≥ λOP since the former includes dominance 
terms; the magnitude of the ratio:
(λSib – 1)     Cov(X,Sib)                               ______________ = __________________
(λOP – 1)     Cov(X,OP)
reﬂ ects the relative importance of dominance eﬀ ects.
           (λSib – 1)Often ______________ ≈ 1 (Table 1) and so dominance eﬀ ects are
           (λOP – 1)
considered to be negligible. Th is approximate equality 
also implies that common environmental eﬀ ects 
between sibs is not diﬀ erent to that between parent and 
oﬀ spring, and, for many diseases, assuming common 
environmental eﬀ ects are negligible seems plausible. 
Similarly, the ratio:
(λMZ – 1)     Cov(X,MZ)                               ______________ = __________________
(λSib – 1)     Cov(X,Sib)
is expected to be 2 under a model that contains only 
additive genetic variance; if individual risk loci combined 
additively on the risk scale, then only additive variance 
would be observed. Th is ratio is often greater than 2 
(Table 1), implying that epistatic genetic variance on the 
risk scale is not negligible.
Methods
Genetic model
We deﬁ ne K, as before, as the disease prevalence and gx as 
the genetic risk (or probability) of disease of an individual 
given their multilocus genotype of x risk alleles out of a 
possible 2n, where n is the number of loci that contribute 
to the genetic variance of the disease; by deﬁ nition E(g) = K. 
For simplicity, we will assume that all risk alleles have 
equal frequency, p, and equal relative risks, τ, compared 
to the non-risk (wild type allele). We discuss the 
implications of these assumptions later. We assume that 
all loci are independent and that each locus is biallelic 
and is in Hardy-Weinberg equilibrium so that the 
frequency of wild type, carrier and homozygous risk 
genotypes in the population are (1 – p)2, 2p(1 – p) and p2 
and x is distributed Binomial (2n,p), which approximates 
a normal distribution for n > ~5. We also assume random 
mating, no inbreeding and equal fertility of diseased and 
non-diseased individuals.
We consider three widely used genetic models of risk 
that are additive on some underlying scale. We assume 
that risk alleles act additively on the underlying scale 
both within a locus and between loci so that the critical 
contributor to genetic risk of disease is the number of 
risk alleles in an individual’s multilocus genotype. We do 
not consider models that are additive on the risk scale as 
these were rejected by Risch [3] and conﬁ rmed in 
preliminary simulations as being unable to generate the 
patterns of recurrence risks to relatives observed for 
complex genetic diseases. After describing the disease 
risk models, we use numerical analysis and simulation to 
compare them. We compare the models to determine if 
they make the same predictions about observable 
recurrence risks and to investigate which model best ﬁ ts 
the observed estimates.
Risch risk model
Additive on the log (risk) = log(g) scale: log(gx) = 
log(fn) + x log(τ)
Multiplicative on the risk (g) scale: gx = fn τx
Under this model the relative risk of the risk allele 
compared to the other (wild-type) allele is τ, the homo-
zygous risk genotype at each risk locus is τ 2 and the risks 
of the individual loci are multiplicative on the risk scale 
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gx = fnτ x , where fn is the probability of disease in a person 
with only wild-type alleles at all n contributing loci and fn 
can be expressed explicitly as fn = K/(1 + p(τ – 1))2n [10]. 
Th is model of disease risk was introduced by Risch [3,11] 
and is the model that we [10] and others [2,12,13] have 
used in the prediction of genetic risk to disease from 
multiple loci. Th e multiplicative Risch model is attractive 
because of its mathematical properties, but an undesir-
able feature (often not apparent in the mathe matical 
expressions) is that there is no constraint placed on gx, so 
that under some combinations of model parameters the 
probability of disease can have impossible values greater 
than 1 (that is, gx >1 for some x). Th is occurs when 
x  ≥  –ln(fn)/ln(τ) (after solving fnτ x = 1). We deﬁ ne the 
constrained Risch (CRisch) model to be the same as the 
Risch model except that gx is truncated to 1 [13]. In this 
case, if K is considered known, fn must be derived by 
numerically solving K = E(g) for fn assuming that n, p and 
τ are known.
Odds of risk model
Additive on the logit of risk scale: logit(risk) = 
log(gx/(1 – gx)) = log(cnK/(1 – K)) + xlog(γ)
Multiplicative on the odds of risk scale: Odds = 
gx/(1 – gx) = γx cnK/(1 – K) = γx Cn
and so gx = γx Cn/(1 – γx Cn)
Under this model, gx/(1 – gx) is the odds of disease given 
the multilocus genotype and Cn = cnK/(1 – K) is the odds 
of disease for an individual with all wild-type alleles at 
the n contributing loci, following Janssens et al. [4] and 
Lu and Elston [2]. Th e odds of disease without any 
information on multilocus genotype is K/(1 – K). Under 
this model the relative odds of risk of carriers and the 
homozygous risk genotypes are γ and γ2, where γ is the 
odds of the risk and where the γ are multiplicative on the 
odds of disease risk scale across loci. Th ere is no explicit 
solution for K = E(gx) so that an explicit expression for cn 
cannot be derived. For given input parameters cn is 
derived by solving K= E(gx) numerically. Janssens et al. [4] 
used the approximation of cn = c1, but in preliminary 
studies we recognized that this approximation meant that 
the equality of E(gx) with the input (and key benchmark) 
parameter K was lost.
Probit of risk model or liability threshold model
Additive on an underlying liability scale: ux = (x – 2np)a                                                                         ux – tProbit on the risk scale: gx = Φ ( ______________ )                                                                      √(1 – h 2L)
Under this model we deﬁ ne a to be the eﬀ ect of a risk 
allele on the underlying liability scale and ux is the genetic 
value on the underlying scale of an individual with x risk 
alleles, distributed about a mean of zero (since the mean 
number of risk alleles is 2np). Φ is the cumulative normal 
distribution function and t is a constant. Th e liability
threshold model [14-16] assumes that liability to disease 
is normally distributed and that the presence of the 
disease arises if the liability exceeds a threshold, with the 
threshold positioned so that the proportion of the 
population that exceeds the threshold is equal to the 
population prevalence, K. Th e threshold, t, is derived 
from the inverse probability of the normal distribution, 
t = Φ-1(1 – K), Φ(t) = 1 – K; for example, if K = 0.05, t = 
1.645. Th e model is parameterized in terms of variance 
components and heritability (h 2L) on the underlying 
liability scale and can be scaled so that the phenotypic 
variance is 1. An individual’s liability to disease is the sum 
of a genetic component (purely additive on this scale) 
distributed N(0,h 2L) and an environmental component 
distributed N(0,1-h 2L). Th e number (that is, n) and 
frequency (that is, p) of risk alleles determine the value of a:
                                                     h 2L a = √ __________________
                                               2np(1 – p)
Although this model is often referred to as the liability 
threshold model, we will use the name ‘Probit model’ so 
that all three models are named on the risk scale.
Relationship between relative risk (τ) and odds ratio (γ)
Under the Risch model, considering a single locus, the 
risk of the heterozygote is τ and the homozygote relative 
to the wild-type homozygote is τ2. Under this model the 
heterozygous odds ratio is:
ORhet = τ(1 – f1)/(1 – τ f1)
Similarly, the homozygous odds ratio:
ORhom= τ 2(1 – f1)/(1 – τ 2f1)
Th erefore, ORhom > OR2het. In contrast, under the Odds 
model ORhet = γ, ORhom= γ2 and ORhom/OR2het = 1. For 
example, K = 0.1, p = 0.1, τ = 2 under the Risch model, we 
can see that ORhet = 2.49 and ORhom/OR2het = 1.13, which 
shows the Risch and Odds models to be quite diﬀ erent. 
However, under parameters more relevant to human 
disease, for example, K = 0.01, p = 0.1, λ = 1.05, then 
ORhet = 1.0506 and ORhom/OR2het = 1.00003. Hence, odds 
risks and relative risks are often used interchangeably 
because, at the single locus level, they are equivalent for 
practical purposes. However, under a multi-locus model, 
the diﬀ erences between the models compound. Estab-
lish ing a mathematical relationship between the multi-
locus models is not tractable. So we have investigated this 
relationship by simulation.
Comparison of models
One of the problems with comparing the models is to 
ﬁ nd a fair benchmark. We chose two parameters that are 
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directly measurable in real populations for benchmarking 
models: disease prevalence and the eﬀ ect size of a single 
risk allele. To achieve this benchmarking, four input 
parameters were needed for the Probit model from which 
all other variables are derived: disease prevalence, 
number of risk loci, frequency of risk allele and 
heritability on the liability scale (that is, K, n, p and h 2L). 
To benchmark our comparisons, we set τ, the eﬀ ect size 
of a single risk allele, to be equal to g2np+1/g2npwith g2np+1 
and g2np calculated from the Probit model. We use τ 
together with K, n and p as the input parameters for the 
Risch, CRisch and Odds models. Models are compared 
for the shape of the risk function, gx and on the broad 
sense heritability on the risk scale:
                       1
H 201 = __________________ [E(g2) – E(g))2]             (Equation 2)                 K(1 – K)
where E(g2) = ∑2nx=0   g2xqx, and qx is the probability of an 
individual carrying x risk alleles.
To compare models we have used results from GWAS 
to inform us of realistic values of τ. We use K = 0.1, 0.01, 
0.001, to be representative of common, complex genetic 
diseases and we use K = 0.5 to benchmark comparison at 
the most extreme prevalence rate and maximum 
phenotypic variance (K/(1 – K)) on the risk scale. Since 
the number of loci underlying complex diseases is an 
unknown, we use n =100, 1,000, 10,000 since it is now 
considered unlikely that less than 100 loci will inﬂ uence 
risk to common complex genetic diseases. We examined 
a range of n, p and h 2L, but have limited the results 
reported to situations that generate τ < 2. Although a few 
loci with τ > 2 have been identiﬁ ed (for example, for the 
late age of onset disorder, age related macular degenera-
tion [17]), GWAS results suggest that the average τ will 
be less than this [18]. From simulation of 106 families 
over three generations, we calculate λMZ, λSib, λOP and the 
recurrence risk of disease in grandchildren of aﬀ ected 
grandparents, λOG. From these we calculate H 201 (using 
equation 1) and H 201 ≈ 4(λOG – 1)K/(1 – K), which is an 
estimate of narrow sense heritability that is less 
contaminated by non-additive variance than the estimate 
2(λOP – 1)K/(1 – K). More detailed descriptions of the 
simulations are provided in Additional ﬁ le 1.
Results
Risch versus constrained Risch model
In the unconstrained Risch model we found that the 
occurrence of the impossible probabilities of disease (gx > 1) 
had a signiﬁ cant impact on the results for some realistic 
combinations of parameters. For example, when n = 
1,000, K = 0.1, p = 0.1, τ = 1.1, the mean number of risk 
alleles per person is 200 and gx > 1 when x > 232, which 
occurs with frequency 0.009. Despite the low frequency 
of occurrence, these extreme risks contribute dispro por-
tionately to the genetic variance and heritability. In this 
example, the heritability (calculated using equation 2) is 
0.51, but falls to only 0.17 when these impossible risks are 
truncated to 1.
Combined eff ect of n, p and τ
Results for a representative combination of parameters 
(n = 100, 1,000, 10,000, K = 0.1, 0.01, 0.001, p = 0.1, 0.3 
and h 2L = 0.5, 0.7; Additional ﬁ le 2) show that although the 
broad sense heritability on the observed (that is, H 201; 
Equation 2) scale diﬀ ers markedly between the Probit, 
CRisch and Odds models, there is little dependence on n, 
p and τ provided h 2L is held constant. Th is is because, for a 
given h 2L, the parameters n and p control the variance 
contributed by each locus, so that when n is small, the 
eﬀ ect size of each locus τ is necessarily high. Th ese 
results imply that the key parameter in determining 
heritability on the risk scale is the total genetic variance 
rather than the variance at each locus. Consequently, the 
results are presented in terms of h 2L (see ‘Comparison of 
models’ section above) because this allows translation to 
multiple combinations of n, p and τ.
Shape of risk function and heritabilities on the risk scale
In Figure 1 we illustrate risk functions for combinations 
of parameters relevant to human complex genetic 
diseases. Th e x-axis is the number of risk alleles harbored 
by individuals in a population; theoretically, this can be 
between 0 and 2n, but in practice the number of risk 
alleles takes on the range 2np ± 4√2np(1 - p), that is, 4 
standard deviations about the mean. Th e number of risk 
alleles has an approximate normal distribution since the 
binomial distribution with large n tends to normality. In 
Figure 1, the black dotted line represents the proportion 
of individuals with x or more risk alleles. Th e ‘S’-shaped 
curves are the risks or probability of disease given the 
number of risk loci, rising from gx = 0 to gx = 1. Th e 
positioning of this rise along the x-axis reﬂ ects the 
disease prevalence (that is, K) showing that, for low 
prevalence diseases, a greater number of risk alleles 
relative to the population mean is required for disease. 
Th e steepness reﬂ ects the broad sense heritabilities on 
the risk scale (that is, H 201) so that a steeper rise reﬂ ects a 
higher correlation between genotype and phenotype. Of 
these examples, only when h 2L = 0.2 and K = 0.001 (Figure 
1b) was there no need to constrain the Risch risk model 
as gx never reaches 1 even for the maximum values of x 
found in the population.
Th e relationship between H 201 and τ or h 2L is illustrated 
in Figure 2 and depends on both disease prevalence and 
model. Apparently small diﬀ erences in the risk functions 
can have a big impact on the H 201. For the Probit model 
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H 201 is a function of K, whereas for the CRisch and Odds 
models the dependence on K is of much less importance. 
Th is reﬂ ects the choice of benchmarking between the 
models. In the Probit model, the ratio gx+1/gX decreases as x 
(number of risk alleles) increases, whereas in the CRisch 
model this ratio is constant until the limit on probability of 
disease is reached. Th erefore, the probability of disease 
rises more steeply with number of risk alleles for the 
CRisch model than the Probit model and this is more 
pronounced for rarer diseases when the diﬀ erence 
between gx+1/gX at the average x and a high x is greater for 
the Probit model; the Odds model is intermediate.
Figure 3 presents the estimates of λMZ/λ2Sib across the 
full range of h 2L and for diﬀ erent prevalences. Risch [3] 
predicted this relationship to be 1 under a multiplicative 
model. However, this relationship only holds when K = 
0.5, or as h 2L  0 but becomes <<1 as K decreases and 
h 2L  1, a consequence of the need to constrain the 
probability of disease for an individual (gx) to a maximum 
value of 1. Values of λMZ and λSib and the ratio λMZ/λ2Sib are 
presented for a range of scenarios (Table 2) to allow 
comparison with diseases listed in Table 1.
Th e relationship between h 201 and H 201 is almost the 
same for all models (Figure 4), conﬁ rming the similarity 
Figure 1. Risk functions for the CRisch, Odds and Probit models using parameters relevant to human complex genetic diseases. (a-f) Risk 
or probability (gx) of disease for an individual with x out of 2n risk alleles where the number of risk loci, n = 1,000 and the frequency of each risk 
allele, p = 0.3. The black dotted lines represent the proportion of individuals in the population who have x or more risk alleles. The parameters n, p, 
heritability on the underlying liability scale, h2L, and disease prevalence, K, determine the relative risk of a single locus, τ. The legend lists the resulting 
broad sense heritability on the risk scale, H201 (H2 in the legend). The shape of the risk functions is achieved with other combinations of n and p for 
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of the models on the risk scale. Th e maximum value of 
h 201 is 0.64, which occurs as H 201  1 when K = 0.5 as 
derived by Robertson (Appendix of Dempster and Lerner 
[14]). As K decreases or h 2L increases the proportion of 
H 201 that is additive declines so that, for diseases of 
prevalence ≤ 0.01 almost all of the heritability on the risk 
scale is explained by epistatic variance (as shown by the 
steep increase in the risk function [14]).
Distinguishing between models based on risk to relatives
Although we assume that each risk locus has the same 
individual eﬀ ect size, the models diﬀ er in the way that the 
eﬀ ect sizes combine. In the CRisch model each additional 
risk allele multiplies probability of disease by the same 
amount until the number of risk alleles harbored reaches 
the limit of disease being certain, gx = 1. In contrast, the 
Odds and Probit models have ‘built-in’ constraints so that 
gx ≤ 1, which means that each additional risk allele contri-
butes proportionally less to the probability of disease. 
Th is eﬀ ect can be seen in Figure 1 where the risk function 
is steepest for the CRisch model and least steep for the 
Probit model with the Odds model usually in between 
the other two. Th e steeper the risk function the higher 
the broad sense heritability H 201, so this is usually highest 
for the CRisch model and least for the Probit model. Th is 
eﬀ ect of the risk function on heritability on the risk scale 
also applies to the narrow sense heritability, h 201, so the 
relationship between the two remains constant (Figure 4). 
Th e similarity of the models on the risk scale is not 
perfect as shown by diﬀ erences in λMZ/λ2Sib in Figure  3. 
However, if this ratio is graphed against a function of 
observable parameters, such as H 201 instead of h 2L, the 
diﬀ erences between models are small (Additional ﬁ le 3) 
and could not be demonstrated in practice given the 
sampling errors of the parameters. Th us, the three models 
could not be distinguished using only traditional data, 
that is, recurrence risk of relatives.
Distinguishing between models based on relative risks of 
individual loci, τ
If we identify one or more loci aﬀ ecting a disease, we can 
directly observe the risk in people carrying diﬀ erent 
numbers of risk alleles and compare this with the model 
Figure 2. Relationship between H201 for the CRisch, Odds and Probit models and h
2
L, heritability on the underlying liability scale. (a-c) For 
each h2L, τ is estimated from the Probit model simulation and used as an input for the other models, so that all three models are benchmarked by K 
and τ.  The shape of the relationship is not dependent on the choice of n and p; the τ when h2L = 0.1, 0.3, 0.5, 0.7 and 0.9 are listed above each graph 
when n = 1,000 and p = 0.3. From simulations of a single population of 106 individuals.
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predictions. Th e numerical example in the ‘Relationship 
between τ and γ’ section shows that, for a single locus, 
the models do make diﬀ erent predictions when τ values 
are large but not when they are small, as is expected to be 
the usual case. However, even for small τ values the 
models diﬀ er when all risk loci are included. To obtain 
the same heritability on the risk scale, the models 
required diﬀ erent eﬀ ect sizes (τ) of associated variants 
(Figure 2). Similarly, by comparing Tables 1 and 2, we can 
see that combinations of observed λMZ and λSib corres-
pond to a much lower τ, which translates to a lower 
heritability on the liability scale under the CRisch or 
Odds model compared to the Probit model. For example, 
for a disease with prevalence K = 0.01, λMZ = 52, λSib = 10 
(parameters representative of schizophrenia), the τ for 
n = 1,000 loci each with risk allele frequency p = 0.3 were 
1.19, 1.26 and 1.41 for the CRisch, Odds and Probit 
models, respectively. However, only if it is possible to 
identify the majority of the risk variants will it be possible 
to diﬀ erentiate between the models in practice.
Another way to look at this diﬀ erence between the 
models is that, for a given value of λMZ (or λSib) and τ and 
p, a higher value of n is required for the Probit model 
than for the CRisch model. Th is means that a given risk 
locus with observed τ and p explains a smaller proportion 
of the risk to relatives under a Probit model than under a 
CRisch model. Or equally, it means that the CRisch 
models generate higher risks to relatives in our bench-
marked comparisons - for example, when K = 0.01, n = 1,000, 
p = 0.3, τ = 1.2 and h 2L = 0.5, λMZ for the CRisch, Odds and 
Probit models were 52, 35 and 13, respectively; the λSib for 
the same models were 10, 8 and 4, respectively. If risk loci 
are identiﬁ ed that account for a signiﬁ cant proportion of 
the sibling risk, then it may be possible to test which 
model better ﬁ ts observed data, but this will require a 
large number of families to be genotyped for the risk loci.
Discussion
With the advent of GWAS we are gaining a clearer under-
standing of the genetic architecture of common complex 
diseases. Empirical evidence suggests an architecture of 
many genetic loci with many variants of small eﬀ ect. 
Interest in genomic proﬁ ling, the use of a genome-wide 
markers to predict genetic disease risk, is growing (for 
example, [19,20]), as is the establishment of companies 
oﬀ ering proﬁ ling services. Th e prediction of disease risk 
from many risk loci or markers requires a model that 
combines the eﬀ ects of these loci and the choice of this 
model is the topic of this paper.
Total variance of risk loci is the driving force
We chose two parameters that are directly measurable in 
real populations for benchmarking models: disease 
prevalence (that is, K) and the eﬀ ect size of a single risk 
allele (that is, τ). We recognized that many combinations 
of the number of loci (that is, n) allele frequency (that is, 
p) and τ were consistent with the same heritability on the 
underlying scale in the Probit model (that is, h 2L) and that 
the predictions of all the models were insensitive to the 
exact combination of n, p and τ provided h 2L was held 
constant. Th erefore, we have compared the models while 
holding constant K and h 2L. In Figures 1 and 2 we present 
results for n = 1,000 and p = 0.3, to provide some com-
parison to empirical estimates of τ. Since the distribution of 
genetic risk of disease in a population is driven by total 
genetic variance rather than the variance contributed by 
each locus, it is unlikely that relaxing the restriction of equal 
allele frequencies and eﬀ ect sizes will impact the results; this 
is consistent with the results of other studies [4,10,21].
Although we show that the unconstrained Risch model 
is not a practical model, its mathematical tractability can 
still provide valuable insight into our understanding of 
the factors inﬂ uencing genetic risk. We show (Additional 
ﬁ le 4) that the scaled contribution to the genetic variance 
on the risk scale by each risk allele (v) is a function of p 
and τ, v = p(1 – p)(τ – 1)2/[1 + p(τ – 1)]2 and the total 
genetic variance on this scale is proportional to nv. For 
small values of τ (that is, τ  1), nv ≈ np(1 – p)(τ – 1)2, 
which can be used to derive the proportion of genetic 
variance explained by one locus.
Rejection of simple additive and simple multiplicative 
models on the risk scale
Risch [3], using schizophrenia as an example, was the 
ﬁ rst to show that recurrence risk to relatives in complex 
Figure 4. Relationship between narrow sense (additive) h201 and 
broad sense heritability H201 on the risk scale for diff erent disease 
prevalences (K). From simulations of a single population of 106 
individuals, with h201 calculated as 4(λOG – 1)K/(1 – K) 
 where λOG is the 
recurrence risk of disease in grandchildren of aff ected grandparents 
and H201 calculated from Equation 2.
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diseases is better explained by a multiplicative than an 
additive model of gene action on the risk scale because 
(λMZ – 1)/(λsib – 1) >2 as shown in Table 1. In preliminary 
simulations (not reported) we conﬁ rmed that additivity 
on the risk scale of all risk loci simply could not produce 
the steep rise in probability of disease (Figure 1) neces-
sary to achieve the disease prevalences and recurrence 
risks to relatives typical of complex diseases. In contrast, 
Slatkin [13], under his thesis of exchangeable models, 
demonstrated that an additive model on the risk scale 
could explain complex disease. However, to achieve the 
steep rise in disease risk, he imposed stringent con-
straints, so that the additive eﬀ ect of risk alleles only 
occurred in the (very narrow) range of the number of risk 
alleles associated with the steep rise in probability of 
disease. Outside this range probability of disease was either 
zero or 1. In this way, the shape of the risk function is similar 
to the models that are multiplicative on the risk scale.
Other theoretical studies have used the Risch model 
[2,13], the CRisch model [13], the Odds model [4] and 
the Probit model [22]. Although there is a generally 
accepted dogma that these models are similar, in trying 
to compare studies it is important to know if any diﬀ er-
ences are a function of the choice of risk model. In a 
previous study [10] we made derivations under the 
Risch model and for the parameter combinations 
considered the probability of disease being greater than 
1 was rare. However, in this study, where we have 
considered the full range of parameters, we have 
recognized that under the unconstrained Risch model, 
individuals for whom probability of disease is greater 
than 1 (gx >1) make a huge contribution to the genetic 
variances.
Risch [3] investigating schizophrenia and Brown et al. 
[6] studying ankylosing spondilitis recognized that the 
observed ratio λMZ/λ2Sib was less than one, whereas this 
ratio is expected to be 1 under the Risch model [3]. Th e 
sampling variance on estimates of recurrence rates is high 
and so the greater consistency with multiplicative rather 
than additive models (risk scale) was their main 
conclusion. However, by looking at a range of complex 
diseases (Table 1) there is consistent evidence that λMZ/λ2Sib 
is less than 1, particularly for low prevalence diseases. 
Th ese observed ratios are consistent with our simulation 
results, which show that under the CRisch, Odds and 
Probit models, the ratio λMZ/λ2Sib  1 only as K  0.5 and 
h 2L  0, but under parameters typical of common 
complex genetic diseases λMZ/λ2Sib << 1, particularly as 
K  0 and h 2L  1. Th e mathematical tractability of the 
Risch model has often made it the method of choice in 
theoretical studies and the equality λMZ/λ2Sib = 1 has been 
used to underpin predictions (for example, see the 
Supple ment of Clayton [23]); in the mathematical 
expressions the impact of not constraining the probability 
of disease to be less than 1 is not obvious, but it is 
because of this important constraint that equality λMZ/λ2Sib 
is often much less than 1.
Th erefore, we conclude that the unconstrained Risch 
model is simply not realistic, particularly for parameters 
typical of human complex disease (K < 0.1 and h 2L > 0.5), 
Table 2. Relative risks to relatives of aff ected individuals calculated within the stochastic simulation for Probit, CRisch 
and Odds models
Probit CRisch Odds









0.1 0.1 1.3 1.2 0.99 1.4 1.2 1.00 1.3 1.1 1.00
0.1 0.5 3.2 1.9 0.87 5.6 2.6 0.84 3.9 2.1 0.85
0.1 0.7 4.7 2.4 0.81 7.6 3.0 0.83 6.0 2.8 0.80
0.1 0.95 7.8 3.1 0.82 9.7 3.2 0.92 9.3 3.2 0.90
0.01 0.1 1.9 1.4 0.97 2.4 1.5 1.00 1.7 1.3 1.03
0.01 0.5 13.0 4.4 0.68 51.7 9.9 0.53 34.8 8.1 0.54
0.01 0.7 26.6 7.0 0.54 76.8 12.3 0.51 62.3 11.3 0.49
0.01 0.95 67.3 11.7 0.49 97.0 13.0 0.57 94.6 12.9 0.57
0.001 0.1 2.8 1.7 0.96 4.0 2.0 1.00 1.2 1.1 1.06
0.001 0.5 54.8 10.5 0.49 516.5 41.6 0.30 342.5 34.0 0.30
0.001 0.7 157.8 20.6 0.37 796.8 51.4 0.30 638.5 49.5 0.26
0.001 0.95 599.8 47.5 0.27 989.9 57.6 0.30 968.6 55.9 0.31
h2L  is an input parameter for the Probit model. For each h
2
L  τ is estimated from the Probit model simulation and used as input to the CRisch and Odds model 
simulations. h2L  is used as the benchmark as τ is dependent on n, p and K.
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so here we have made comparisons on the more realistic 
constrained (CRisch) model.
Diff erences between the models unlikely to be detectable 
in practice
Since we reject the additive and Risch models, we 
concen trate on the comparison of the CRisch, Odds and 
Probit models. We chose to compare models with two 
ﬁ xed benchmarks, disease prevalence and eﬀ ect size of 
an individual risk allele, taken at the average number of 
risk alleles (that is, τ). Under this benchmarking, the 
probability of disease associated with carrying the 
minimum number of alleles in the population diﬀ ers 
between models, but in all models this will be very close 
to zero given the number or risk loci now expected to 
contribute to complex genetic disease. Although we 
assume that each risk locus has the same individual eﬀ ect 
size, the models diﬀ er in the way that the eﬀ ect sizes 
combine. For example, a given risk locus with observed τ 
and p explains a smaller proportion of the risk to relatives 
under a Probit model than under a CRisch model. How-
ever, we conclude that for all operational purposes, in the 
foreseeable future, it is unlikely that we will be able to 
distinguish between the models either on the basis of 
recurrence risks to relatives or on the basis of estimates 
of eﬀ ect sizes of risk loci. Slatkin [13] also compared the 
CRisch and Probit models and benchmarked on a range 
of parameters. Our results are complementary to, and 
consistent with, his, although direct comparison is 
prevented by his models distinguishing between hetero-
zygotes and homozygotes at each locus, so that the multi-
plicativity of risk alleles was only between loci and not 
within loci. Inability to distinguish between multi-locus 
risk models on the basis of recurrence risks is perhaps 
not surprising given that Smith [24] was unable to 
distinguish between more extreme models on this basis. 
Ability to distinguish between the models is only possible 
in the very tail of the risk curve and would only be 
achievable if genomic proﬁ les could be constructed using 
measured variants that accounted for the totality of the 
genetic variance. If this were possible, sets of individuals 
could be identiﬁ ed with high predicted risk and the 
proportion succumbing to disease could be measured 
and compared to the proportion expected under diﬀ erent 
models. Such hypothetical scenarios at present seem 
unattainable.
Each individual carries a unique portfolio of risk loci
From Figure 1 it becomes clear that when there are many 
risk loci contributing to disease each of small eﬀ ect, that 
all individuals in the population necessarily carry a large 
number of risk alleles. For example, when 1,000 loci with 
risk alleles of frequency 0.1 underlie a complex disease, 
all individuals in the population carry at least 150 risk 
alleles, an average individual carries 200 risk alleles and, 
when disease prevalence is low and heritability is high, 
most of those with disease carry 230 to 250 risk alleles. 
Since, in this example, there is a total of 2,000 risk alleles, 
each individual will carry their own unique portfolio, 
which could underlie the phenotypic heterogeneity 
typical of many complex diseases.
Large amounts of epistasis on the risk scale despite 
additivity on underlying scales
Our results show that additivity of individual genetic 
variants on some underlying scale can convert to, some-
times considerable, non-additive genetic variance on the 
risk scale, particularly when the disease prevalence is low. 
Th ese results are not new and were presented by Dempster 
and Lerner [14], but are sometimes overlooked. Human 
diseases usually have prevalences of less than 0.1, in 
which case the majority of the genetic variance on the 
risk scale is epistatic. Th ese results imply that the models 
underpinning GWAS already account for one type of 
gene-gene interaction, if each τ could be estimated 
without error. Likewise, our usual models also imply 
genotype-environment interaction on the risk scale 
because the eﬀ ect of an environmental factor is greater in 
people with higher genetic risk. Our deﬁ nition of 
epistasis is one of statistical interaction; the extent to 
which statistical interaction relates to biological or 
functional interaction has been much debated (see [25] 
for a review) and will not become clear until more of the 
genetic variance can be explained by identiﬁ ed genomic 
variants.
True versus estimated τ
We set out to benchmark models on the basis of two 
observable parameters, disease prevalence (that is, K) 
and the eﬀ ect size of a single risk allele (that is, τ). In 
building the models we have assumed that the true τ is 
known and have deﬁ ned it as the eﬀ ect of a single risk 
locus in the background of the average number of risk 
loci. However, the estimates of τ made from experimental 
data may be quite diﬀ erent to these true values. If the 
genotypes at all risk loci were known and a complete 
model was ﬁ tted to the data, then the correct estimate of 
τ would be obtained (within experimental sampling 
error). In practice, however, usually only the eﬀ ect of a 
single risk locus is included in the statistical model and 
under these circumstances we will estimate the eﬀ ect of 
an extra risk allele averaged across all background 
genotypes rather than the eﬀ ect at the mean background 
genotype. Th e eﬀ ect of this may be dependent on the true 
way in which loci combine to inﬂ uence risk of disease, 
which, of course, is unknown. Under the CRisch model of 
Figure 1a, all individuals with >650 risk alleles get the 
disease, so above 650 risk alleles there is no eﬀ ect of an 
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extra risk allele. Conversely, below 650 risk alleles each 
extra risk allele increases the probability of disease by τ. 
Th e experimental estimate will be a weighted average of 
these two estimates (zero and τ). In practice, therefore, 
variants detected with small relative risk may reﬂ ect 
greater biological importance than might otherwise be 
inferred. Under the Probit model the τ calculated at the 
average number or risk loci is:
                                   a – t                     – t
Φ ( ______________ ) / Φ ( ______________ )                               √(1 – h 2L)            √(1 – h 2L)
whereas the τ estimated when a single risk locus is in the 
statistical model is Φ(a – t)/Φ(– t) because then all other 
risk loci are part of the residual variance in liability and 
so the residual variance approaches the phenotypic 
variance, which is 1.0.
Comparison of the models in practice is diﬃ  cult and 
distinguishing between them may be impossible, espe-
cially if the true n is large and the true τ is small. Since we 
have demonstrated that the models are diﬃ  cult to 
diﬀ erentiate, the use of the Probit model, which has 
mathematical tractability and a known relationship 
between the estimates of τ in diﬀ erent genetic back-
grounds, is likely to be the model of choice. Th e estimated 
variance on the liability scale explained by a locus with 
estimated eﬀ ect size τˆ is 2p(1 – p)(τˆ – 1)2/i2 [26], so that 
the estimated eﬀ ect on the liability scale is aˆ(τˆ – 1)/i, 
where i is the mean liability of the diseased group, i = z/
K, where z is the height of the normal curve at the 
threshold t.
Limitations
Th e true genetic architecture (in terms of number, fre-
quency and eﬀ ect size of risk variants and the way in 
which they combine) is unknown and may be quite 
diﬀ erent for the diﬀ erent diseases listed in Table 1. For 
simplicity, we have described disease in terms of aﬀ ected/
unaﬀ ected, ignoring time-dependent onset, and we have 
ignored phenotypic heterogeneity (which may reﬂ ect 
genetic heterogeneity) in the deﬁ nition of disease status 
and other real-life complications. In principle, our 
approach could reﬂ ect any deﬁ nition of disease if the 
genetic epidemiology and genetic risk variants can be 
deﬁ ned - for example, early and late onset disease may be 
considered as diﬀ erent diseases - but despite this any 
simple model is likely to be a poor representation of 
disease. None of the models we have considered are likely 
to be the true model, but since they can all generate 
recurrence risks consistent with complex genetic diseases 
(given the right combination of parameters), they can 
give useful insight until empirical data provide evidence 
for them to be rejected. Th ese simple models provide 
some boundaries, demonstrating some properties that 
must be upheld by the true genetic architecture in order 
to be consistent with observed data.
Conclusions
In this paper we set out to compare diﬀ erent models that 
combine the eﬀ ects of multiple risk loci into an overall 
genetic risk. We conclude that a model that is additive or 
multiplicative on the risk scale across all loci is incom-
patible with the observed recurrence risks to relatives. 
Th e constrained multiplicative (CRisch), Odds and Probit 
models are all compatible with the observed data and, in 
fact, it is diﬃ  cult to distinguish between them when the 
relative risk at an individual locus is small. Importantly, 
we show that the unconstrained multiplicative (Risch) 
model, often used in theoretical studies because of its 
mathematical tractability, is not a realistic model as 
impossible probabilities of disease are implied. Speciﬁ -
cally, the multiplicative Risch model generates a 
relationship of λMZ/λ2Sib = 1, but we have demonstrated 
that this not possible under many disease scenarios and 
occurs in the theoretical derivation because probabilities 
of disease are not constrained and can exceed 1. We have 
demonstrated that under more realistic models in which 
probabilities of disease are constrained to 1, the ratio 
λMZ/λ2Sib is often much less than 1, a result that is 
consistent with empirical estimates from a range of 
diseases. Finally, we conclude that it will only be possible 
to distinguish between the CRisch, Odds and Probit 
models in practice if genetic risk proﬁ les are able to 
reconstruct the majority of the known genetic variance; 
this is unlikely for the foreseeable future.
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risk of disease in relatives of diseased individuals for relatives of type R; λSib, 
recurrence risk of disease in sibs of diseased individuals; τ, the risk (probability) 
of disease of a risk allele relative to the other (wild-type) allele for a single locus 
(for the unconstrained Risch model τ = gx–1/gx for all x = 0, 2n – 1); a, additive 
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contributing loci; gx, the genetic risk (or probability) of disease of an individual 
given their multilocus genotype of x risk alleles; h201, narrow sense (that is, 
additive genetic) heritability on the risk scale; h2L, heritability on the liability 
scale, on this scale all genetic variance is additive; H201, broad sense (that is, total 
genetic) heritability on the risk scale - on this scale the phenotype, disease, is 
either not diseased (0) or diseased (1); K, disease prevalence in a population; 
KR, disease prevalence in relatives of diseased individuals for relatives of type 
R; n, the number of loci that contribute to the genetic variance of the disease; 
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